Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EBITDA Margin for 9 consecutive years, with 6932.81% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBITDA Margin fell 559166.0% year-over-year to 6932.81%, compared with a TTM value of 40525.52% through Sep 2025, down 3961723.0%, and an annual FY2024 reading of 15535.6%, down 1411403.0% over the prior year.
  • EBITDA Margin was 6932.81% for Q4 2024 at Avalo Therapeutics, down from 9251.81% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 9251.81% in Q3 2024 and bottomed at 8202.28% in Q4 2021.
  • Average EBITDA Margin over 5 years is 1634.51%, with a median of 1238.35% recorded in 2022.
  • The sharpest move saw EBITDA Margin tumbled -711052bps in 2021, then soared 1146706bps in 2024.
  • Year by year, EBITDA Margin stood at 1091.76% in 2020, then tumbled by -651bps to 8202.28% in 2021, then skyrocketed by 88bps to 988.17% in 2022, then crashed by -36bps to 1341.16% in 2023, then crashed by -417bps to 6932.81% in 2024.
  • Business Quant data shows EBITDA Margin for AVTX at 6932.81% in Q4 2024, 9251.81% in Q3 2024, and 1341.16% in Q4 2023.